Literature DB >> 17072917

Circulating, soluble forms of major histocompatibility complex antigens are not exosome-associated.

Philippa A MacKay1, Salome Leibundgut-Landmann, Norbert Koch, Amy C Dunn, Walter Reith, Ralph W Jack, Alexander D McLellan.   

Abstract

In vitro studies have shown that soluble MHC (sMHC) released by cell lines is bound to nano-vesicles termed exosomes. It is thought that exosomes may represent the major reservoir of sMHC class I and II molecules in biological fluids. However, most studies have been confined to in vitro assays performed with cell lines. We show here that sMHC in the serum or plasma differs from exosome-bound sMHC in five ways: In contrast to exosome-associated sMHC, circulating sMHC is of low density, has a low apparent molecular mass (40-300 kDa) and is not detergent-labile. Moreover, the majority of MHC class II isoforms and MHC class I in blood are not physically linked and circulating HLA-DR is accessible to an antibody specific for the HLA-DR alpha-chain intracellular epitope, which is masked by its association with cellular or exosomal membranes. Finally, utilizing transcriptional activator of murine MHC class II (C2ta) promoter-mutant mice, we showed that the release of sMHC class II into the circulation is dependent on the C2ta pI promoter, but not pIII or pIV. This suggests that myeloid dendritic cells and/or macrophages, which preferentially use promoter pI of the C2ta gene, produce most of the sMHC class II found in the circulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072917     DOI: 10.1002/eji.200636041

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Soluble MHC-II proteins promote suppressive activity in CD4+ T cells.

Authors:  Katerina Bakela; Nikos Kountourakis; Michalis Aivaliotis; Irene Athanassakis
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 2.  Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.

Authors:  Katerina Bakela; Irene Athanassakis
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

3.  CD169 mediates the capture of exosomes in spleen and lymph node.

Authors:  Sarah C Saunderson; Amy C Dunn; Paul R Crocker; Alexander D McLellan
Journal:  Blood       Date:  2013-11-19       Impact factor: 22.113

4.  Membrane vesicles released by intestinal epithelial cells infected with rotavirus inhibit T-cell function.

Authors:  Alfonso Barreto; Luz-Stella Rodríguez; Olga Lucía Rojas; Marie Wolf; Harry B Greenberg; Manuel A Franco; Juana Angel
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

5.  TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.

Authors:  Rony Dahan; Moran Tabul; Yuan K Chou; Roberto Meza-Romero; Shayne Andrew; Adolph J Ferro; Gregory G Burrows; Halina Offner; Arthur A Vandenbark; Yoram Reiter
Journal:  Eur J Immunol       Date:  2011-04-12       Impact factor: 5.532

6.  MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles.

Authors:  Hongqi Xin; Yi Li; Zhongwu Liu; Xinli Wang; Xia Shang; Yisheng Cui; Zheng Gang Zhang; Michael Chopp
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

7.  Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules.

Authors:  Hui Jin; Kazuki Kishida; Noriko Arase; Sumiko Matsuoka; Wataru Nakai; Masako Kohyama; Tadahiro Suenaga; Ken Yamamoto; Takehiko Sasazuki; Hisashi Arase
Journal:  Sci Adv       Date:  2022-03-04       Impact factor: 14.136

8.  Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles.

Authors:  Morad-Rémy Muhsin-Sharafaldine; Sarah C Saunderson; Amy C Dunn; James M Faed; Torsten Kleffmann; Alexander D McLellan
Journal:  Oncotarget       Date:  2016-08-30

Review 9.  The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design.

Authors:  Amy L Kessler; Marco J Bruno; Sonja I Buschow
Journal:  Vaccines (Basel)       Date:  2020-12-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.